MENLO PARK, Calif., Feb. 23, 2011 /PRNewswire/ — SRI
International, an independent nonprofit research and development
organization, announced today that two new principal scientists,
Dave Anderson, Ph.D., and William Thomsen, Ph.D., have joined its
Center for Advanced Drug Research (CADRE) in Shenandoah Valley,
Virginia.
Dr. Anderson will serve as principal scientist in CADRE’s
proteomics group. He has more than 20 years of experience applying
mass spectrometry and proteomics methods to a variety of scientific
problems. At SRI, he will apply those methods to set up biomarker
analytics for specific disease areas and study host-pathogen
interactions and pathogen drug resistance mechanisms.
Prior to joining SRI, Dr. Anderson was senior director of
proteomics at Catalyst Biosciences and research fellow for
proteomics and target discovery at Rigel Pharmaceuticals. Earlier,
he headed the protein chemistry department at Khepri
Pharmaceuticals and then at Arris Pharmaceutical following its
acquisition of Khepri. In between his positions in the biotech
industry, he was a research professor at the University of
Oregon.
Dr. Anderson received his Ph.D. from the University of Oregon.
He has authored more than 60 publications and holds 42 U.S.
patents.
Dr. Thomsen will serve as principal scientist in CADRE’s
metabolic diseases group, where he will lead research pertaining to
metabolic diseases.
He joins SRI with more than 25 years of experience in
pharmaceutical drug discovery, with an emphasis on target
validation, assay development, high throughput screening, and
molecular pharmacology. He has experience with several classes of
discovery targets, including G protein coupled receptors, within
multiple therapeutic areas, including: disorders of the central
nervous system; endocrine, metabolic, cardiovascular, and
immunological diseases; and cancer. Most recently, he served as the
director of molecular pharmacology at Arena Pharmaceuticals.
‘/>”/>
